Type Public Area served Worldwide | Industry Biopharmaceutical Founded 1999 | |
 | ||
Headquarters Yeonsu-gu, Incheon, South Korea Key people Jung Jin Seo, Chairman & CEO Products Remsima™, Biosimilar Drug | ||
Celltrion healthcare ct p13
Celltrion Healthcare is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.
Contents
History
In 1999, Nexol, Inc. (now Celltrion Healthcare Co., Ltd.) a global business management consulting firm founded. In 2002, Celltrion, Inc. a biopharmaceutical company founded. In 2008, Nexol, Inc. and Celltrion, Inc. established a global distribution agreement. In 2009, Distribution channels were established in America, Oceania, Europe (Hospira) and Nexol, Inc. renamed as Celltrion Healthcare Co., Ltd. In 2010, Distribution channels were established in Japan (Nippon Kayaku), Commonwealth of Independent States (CIS), Eastern Europe, and the Middle East (Egis). In 2013, Distribution channels were added in Europe (Mundipharma, Biogaran, Kern)
Products
The company’s products are manufactured at mammalian cell culture facilities designed and built to comply with the United States FDA’s cGMP, and the European Medicines Agency’s GMP standards.
Inline product
Remsima™(infliximab) is a biosimilar monoclonal antibody against tumor necrosis factor alpha (TNF-α), approved by the European Medicines Agency(EMA) for treatment of (1) rheumatoid arthritis, (2) adult Crohn’s disease, (3) pediatric Crohn’s disease, (4) ulcerative colitis, (5) pediatric ulcerative colitis, (6) ankylosing spondylitis, (7) psoriatic arthritis, and (8) psoriasis. In 2012, Remsima™(infliximab) was approved by the Republic of Korea’s Ministry of Food and Drug Safety(MFDS), previously known as Korea Food and Drug Administration and In 2013, Remsima™(infliximab) became the world’s first biosimilar monoclonal antibody(mAb) approved by the European Medicines Agency(EMA).
Herzuma is a biosimilar trastuzumab approved by the Ministry of Food and Drug Safety of the Republic of Korea for treatment of early and advanced (metastatic) HER2+ breast cancer as well as advanced (metastatic) stomach cancer. Herzuma is a HER2+ breast cancer therapy designed to treat aggressive HER positive metastatic and adjuvant breast cancer, as well as HER2 positive adenocarcinoma of the stomach that has spread (metastatic or advanced gastric cancer).
Biosimilar mAb Pipeline Product
CT-P10 is a candidate biosimilar rituximab that targets CD20 molecule primarily found on the surface of B-cells. Its target indications are rheumatoid arthritis, non-Hodgkin's lymphoma and chronic lymphocytic leukemia.